Last updated: 11/04/2018 06:03:30

A Methodology Study To Look At Genes In Lung Cells And Tissue From Asthmatic Patients

GSK study ID
CRB100706
Clinicaltrials.gov ID
NCT00331292
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Other
Other
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A study to identify a transcriptomic profile indicative of cycle AMP pathway activation in the lung
Trial description: The primary goal of this study is to identify a gene or panel of genes which are differentially expressed in lung cells and tissue from asthmatic patients following administration of Ipratropium bromide and eiTher nebulised Albuterol or saline. Each subject in this study will undergo two bronchoscopies.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
30
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Prospective
Clinical publications:
Not applicable
Medical condition
Asthma
Product
Not applicable
Collaborators
Not applicable
Study date(s)
August 2006 to August 2006
Type
Observational
Phase
Not applicable

Participation criteria

Sex
Female & Male
Age
18 - 45 Years
Accepts healthy volunteers
no
  • Inclusion criteria:
  • Have a history of intermittant asthma.
Inclusion and exclusion criteria
Inclusion criteria:
  • Inclusion criteria:
  • Have a history of intermittant asthma.
  • Have asthma symptoms less than once per week.
  • Have no other significant disease.
  • Do not take regular oral or inhaled steroids.
  • Are a non-smoker for the past 12 months with a pack history of less than 5 years. Exclusion criteria:
  • Have a history of drug or alcohol abuse.
  • Have poorly controlled asthma or a history of life-threatening asthma.
  • Have a history of hypersensitivity to bronchodilators.
  • Are unable to abstain from inhaled steroids from 14 days prior to the first study visit until completion of the study.
  • Have received oral steroids within 3 months of study entry.
  • Have been hospitalized for your asthma within 3 months of study entry.
  • Have had treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19104
Status
Terminated/Withdrawn
Contact us

Study documents

No study documents available.

Results overview

No study documents available

Recruitment status
Other
Actual primary completion date
Not applicable
Actual study completion date
2006-22-08

Plain language summaries

Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

Additional information about the trial

Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website